Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

Published:2024-07 Issue:7 Volume:9 Page:632-645
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Ovchinsky Nadia,Aumar Madeleine,Baker Alastair,Baumann Ulrich,Bufler Philip,Cananzi Mara,Czubkowski Piotr,Durmaz Özlem,Fischer Ryan,Indolfi Giuseppe,Karnsakul Wikrom W,Lacaille Florence,Lee Way S,Maggiore Giuseppe,Rosenthal Philip,Ruiz Mathias,Sokal Etienne,Sturm Ekkehard,van der Woerd Wendy,Verkade Henkjan J,Wehrman Andrew,Clemson Christine,Yu Qifeng,Ni Quanhong,Ruvido Jessica,Manganaro Susan,Mattsson Jan P

Funder

Albireo Pharma Inc

Publisher

Elsevier BV

Reference30 articles.

1. Alagille syndrome: pathogenesis, diagnosis and management;Turnpenny;Eur J Hum Genet,2012

2. Systematic review: the epidemiology, natural history, and burden of Alagille syndrome;Kamath;J Pediatr Gastroenterol Nutr,2018

3. Outcomes of childhood cholestasis in Alagille syndrome: results of a multicenter observational study;Kamath;Hepatol Commun,2020

4. Studies of the aetiology of neonatal hepatitis and biliary atresia;Danks;Arch Dis Child,1977

5. Consequences of JAG1 mutations;Kamath;J Med Genet,2003

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring odevixibat’s efficacy in alagille syndrome: insights from recent clinical trials and IBAT inhibitor experiences;Expert Opinion on Pharmacotherapy;2024-08-12

2. IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?;Hepatology;2024-07-25

3. Heritable Chronic Cholestatic Liver Diseases: A Review;Journal of Clinical and Translational Hepatology;2024-06-17

4. Positive phase III trials for ileal bile acid transporter inhibitors;Nature Reviews Gastroenterology & Hepatology;2024-05-23